within Pharmacolibrary.Drugs.ATC.L;

model L01EX24
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.81,
    Cl             = 0.00016633333333333336,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0544,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011383333333333334,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.107,
    k12             = 21.2,
    k21             = 21.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX24</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Surufatinib is an oral small molecule tyrosine kinase inhibitor targeting VEGFR, FGFR1, and CSF-1R. It is developed for the treatment of neuroendocrine tumors (NETs) and has received approval in China for the treatment of non-pancreatic neuroendocrine tumors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adult patients with advanced solid tumors, typically Asian (Chinese) individuals. Data most extensively reported for the oral administration of surufatinib at steady state.</p><h4>References</h4><ol><li><p>Lu, X, et al., &amp; Chen, Z (2021). Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. <i>Expert review of anticancer therapy</i> 21(9) 917–926. DOI:<a href=&quot;https://doi.org/10.1080/14737140.2021.1944110&quot;>10.1080/14737140.2021.1944110</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34142932/&quot;>https://pubmed.ncbi.nlm.nih.gov/34142932</a></p></li><li><p>Xu, J (2021). Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). <i>Therapeutic advances in medical oncology</i> 13 17588359211042689–None. DOI:<a href=&quot;https://doi.org/10.1177/17588359211042689&quot;>10.1177/17588359211042689</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34484432/&quot;>https://pubmed.ncbi.nlm.nih.gov/34484432</a></p></li><li><p>Li, K, et al., &amp; Sai, Y (2020). Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans. <i>Current drug metabolism</i> 21(5) 357–367. DOI:<a href=&quot;https://doi.org/10.2174/1389200221666200514131721&quot;>10.2174/1389200221666200514131721</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32407271/&quot;>https://pubmed.ncbi.nlm.nih.gov/32407271</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX24;
